Replimune Group stock has delivered a very strong 199.4% return over the past year, yet the broader valuation checks still flag the shares as leaning expensive rather than a clear bargain.

• Over the last 12 months, Replimune Group has returned 199.4%, which puts extra focus on whether the recent share price strength is already baking in optimistic expectations.
• The FDA advisory panel endorsement of RP1 for advanced melanoma can support higher growth expectations for the business, while ongoing securities fraud investigations and class action lawsuits linked to the later FDA rejection of RP1 may weigh on how investors price risk.
• On Simply Wall St's valuation checks, Replimune Group passes only 2 of 6 measures. This means the stock currently screens as not clearly cheap on a broad view of price versus fundamentals 2/6.

The issue now is whether Replimune Group's recent rally leaves enough room in the valuation for the regulatory and legal uncertainties still in play.

Has Replimune Group Run Too Far on Book Value?

P/B is usually a useful way to look at clinical stage biotechs like Replimune Group because investors are often paying more for the pipeline and know-how than for current earnings.

Replimune Group currently trades on a P/B of 8.6x, compared with an industry average of about 2.4x and a peer group average of roughly 3.4x. That is a large premium to both the broader biotech sector and closer peers, which suggests the market is pricing the stock well above the value of its net assets.

The FDA advisory panel support for RP1 has clearly lifted expectations, yet the ongoing securities fraud investigations and class actions underline the risk that the balance sheet alone may not justify such a rich multiple. On this P/B lens, the stock screens as expensive relative to both its sector and peer benchmarks.

On the current price-to-book multiple, Replimune Group looks overvalued compared with typical biotech peers.

The Replimune Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Replimune Group valuation puzzle leaves off by spelling out which future paths for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. Each narrative links its number to a clear view on how Replimune Group's growth, profitability and risk profile could evolve, which you can revisit on the Community page as new information emerges.

Share a narrative on Replimune Group to provide a number-driven view on whether the FDA advisory panel endorsement of RP1 and the later legal actions linked to the FDA rejection are fully reflected in the stock, and then track how that thesis holds up as new results and disclosures arrive.

Do you think there's more to the story for Replimune Group? Head over to our Community to see what others are saying!

The Bottom Line

Replimune Group screens as overvalued on traditional market multiples, with a clear premium to sector and peer benchmarks despite only modest support from broader valuation checks. That does not rule out further upside, but it does mean the market is already paying up for the RP1 opportunity while legal and regulatory questions remain unresolved. The key debate from here is whether Replimune Group can deliver enough clinical and regulatory progress on RP1 to keep that rich multiple intact, or whether the valuation needs to reset if expectations prove too optimistic.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.